';
CLOSE
Tags Posts tagged with "treatment"

treatment

0 758
Image by Tom und Nicki Löschner from Pixabay

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) has released its Compulsive and Problem Gambling Annual Report, highlighting prevention and treatment efforts for state fiscal year (SFY) 2024/25.

This year’s report reflects continued progress in connecting Pennsylvanians to help and expanding prevention outreach across the Commonwealth.

Highlights include:

  • Continued growth in texts and online chats to the 1-800-GAMBLER helpline;
  • Increased admissions to problem gambling outpatient treatment programs — up 24 percent from the previous year;
  • Forty-one county drug and alcohol offices engaged in prevention programming — a 21 percent increase from the prior year; and
  • Nearly 820,000 Pennsylvanians reached through prevention programming — a 28 percent increase from the prior year.

Read the full report.

0 1531

Message from the Department of Health (PA DOH):

With the recent rise in COVID-19 case counts across the Commonwealth and the country, the Pennsylvania Department of Health (PA DOH) wants long-term care facilities (LTCFs) to be aware of the multiple ways to access lifesaving COVID-19 treatment and preventive products.

We distribute the following outpatient therapeutics directly to LTCFs that enroll in the PA DOH network:

  • Treatment: Oral antivirals (Paxlovid & Lagevrio);
  • Treatment: Monoclonal antibodies (Bebtelovimab); and
  • Preventive: Monoclonal antibodies for pre-exposure prophylaxis (Evusheld).

Stocking therapeutics on-site can help eligible patients access preventive protection and receive timely treatment, which must be initiated within a matter of days from symptom onset. Most patients who test positive for COVID-19 are eligible for treatment.

The one-page guide for LTCFs covers how to enroll in the PA DOH therapeutics network. The first step is to complete our therapeutics enrollment form. You will receive additional instructions after form submission. To enroll, your facility will need a pharmacy license and/or a licensed medical director to take responsibility. If you do not have either of these, please reference the guide for alternative options to access COVID-19 therapeutics.

In addition to reviewing the guide, we appreciate you sharing it with other relevant LTCF stakeholders.

If you have any questions, please do not hesitate to reach out via email. Thank you for all that you do to protect vulnerable residents across the Commonwealth. We appreciate your partnership in the fight against COVID-19.

0 1787

Act 126 of 2020 amended the original 2012 Methadone Death and Incident Review (MDAIR) Act, which established the creation of a team to review methadone-related deaths or incidents, to go beyond methadone and include a review of death and incidents related to any Food and Drug Administration (FDA)-approved medication to treat opioid use disorder as a primary, secondary, or contributing factor to a death or incident.

As a result of the new law, the Pennsylvania Department of Drug and Alcohol Programs selected a new MDAIR team to review medication-related deaths, communicate concerns, and develop best practices to prevent future medication-related deaths and incidents.

A list of the new team members can be found here.

© 2021 - Rehabilitation & Community Providers Association